# $\beta$ -Adrenergic Blockade by 3-[3-(Substituted amino)-2-hydroxypropoxy]-5-hydroxybenzyl Alcohols


Charles F. Schwender,\* Russell E. Pike, John Shavel, Jr.,

Department of Organic Chemistry

#### and Harvey R. Kaplan

Department of Pharmacology, Warner-Lambert Research Institute, Morris Plains, New Jersey 07950. Received June 13, 1974

Recently, a new  $\beta$ -sympathomimetic agent, 3-[3- $\alpha$ -(tertbutylaminomethyl)]-5-hydroxy-*m*-xylene- $\alpha$ , $\alpha'$ -diol (1), was reported which selectively stimulated the  $\beta_2$ -adrenergic receptors.<sup>1</sup> It was of interest to determine the effect on biological activity of replacing the ethanolamino (1) side chain by an oxypropanolamino (2a) group. A similar modification of isoproterenol gave an analog (3) which was reported to possess  $\beta$ -sympathomimetic activity similar to epinephrine.<sup>2</sup>



**Chemistry.** Reaction of methyl 3,5-dihydroxybenzoate (4) with 1 equiv of benzoyl chloride gave the corresponding methyl 3-benzoyloxy-5-hydroxybenzoate (5) which was then benzylated using benzyl bromide to give methyl 3benzoyloxy-5-benzyloxybenzoate (6). The benzoyl group of 6 was removed by trans esterification with MeOH and ptoluenesulfonic acid and gave methyl 3-benzyloxy-5-hydroxybenzoate (7). Reaction of 7 with epichlorohydrin in MeOH containing NaOH gave the intermediate methyl 3-benzyloxy-5-(2,3-epoxypropoxy)benzoate (8) which was further reacted with the appropriate amine, such as *tert*butylamine. The compound obtained, methyl 3-benzyloxy-5-[3-(*tert*-butylamino)-2-hydroxypropoxy]benzoate

Scheme I


(9a), was reduced with LiAlH<sub>4</sub> and gave 3-benzyloxy-5-[3-tert-butylamino)-2-hydroxypropoxy]benzyl alcohol as product 10a. Catalytic debenzylation of 10a gave the desired product 2a (Scheme I).

The corresponding 3,4-dimethoxyphenylethyl analog in the benzophenone (11) and tetralone (12) series of  $\beta$ blockers was prepared from known epoxide intermediates<sup>3,4</sup> using the method for the preparation of 9b.

The unusual CHCl<sub>3</sub> solubility of the hydrochloride salts of analogs **9b**, **11**, and **12** allowed a method of separation of the product from 3,4-dimethoxyphenylethylamine. After an acid extraction of the crude mixture of amines in CHCl<sub>3</sub>, the desired product hydrochloride remained in the CHCl<sub>3</sub> phase. A basic wash of the CHCl<sub>3</sub> phase followed by evaporation of the solvent gave the desired product.

**Pharmacology.** The  $\beta$ -adrenergic receptor agonist, antagonist, and direct myocardial depressant effects of this series of compounds were evaluated in barbiturate anesthetized, bilaterally vagotomized mongrel dogs. Dogs were generally either pretreated with reserpine (0.5 mg/kg ip for 2 days and used on the day 3) or the ganglion blocker ansolysen (2 mg/kg iv) prior to the experiments. Reserpinization or ganglion blockade suppressed resting sympathetic tone and facilitated evaluation for intrinsic sympathomimetic and direct myocardial depressant actions. Control responses to isoproterenol (0.3  $\mu$ g/kg iv) were established after which compounds were administered intravenously on a half log dose schedule (0.03-10.0 mg/kg) at 20-min intervals. Isoproterenol challenges were interposed midway between doses of the drug in order to evaluate  $\beta$ adrenergic blockade of heart rate. Results obtained from one or a small number of dogs were reliable and served as a basis for further studies on selected analogs.

The compounds were also evaluated for antiarrhythmic activity in ouabain-intoxicated dogs. Ouabain was administered in sequential iv doses (40, 20, 10  $\mu$ g/kg, etc.) at 15or 30-min intervals until a stable ventricular tachycardia



No.	Compound	$\mathrm{Dose},^e$ $\mathrm{mg/kg};$ 100% eta-blockade	Intrinsic act.	Direct myocardial depression, dose, mg/kg
2a	HO CH <sub>2</sub> CHOHCH <sub>2</sub> NHC(CH <sub>4</sub> ) <sub>2</sub>	0.1-0.3	None <sup>2</sup>	>3
<b>2</b> b	OCH <sub>2</sub> CHOHCH <sub>2</sub> NHCH <sub>2</sub> CH <sub>2</sub> HO CH <sub>2</sub> OH	0.3-1.0 <sup>f</sup>	Yes <sup>b</sup>	10-30
11	O OCH <sub>2</sub> CHOHCH <sub>2</sub> NHCH <sub>2</sub> CH <sub>2</sub> COCH, OCH	1-3	None $^{\circ}$	1-3
12	OCH,CHOHCH,NHCH,CH,CH,COCH,	1-3	None <sup>d</sup>	1-3
Propranolol	OCH2CHOHCH2NHCH(CH3)2	0.3	None <sup>d</sup>	1-3

<sup>a</sup>Ganglion blocker pretreatment. <sup>b</sup>Methods utilizing ganglion blocker and reserpine pretreatment were employed. <sup>c</sup>No pretreatment. <sup>d</sup>Reserpine pretreatment. <sup>e</sup>Dose of antagonist sufficient to block positive chronotropic response to isoproterenol  $(0.3 \ \mu g/kg \ iv)$ . <sup>j</sup>Compound **2b** was the only analog tested which demonstrated cardioselectivity. Doses causing 100% blockade of heart rate did not block blood pressure.

appeared. The drug was administered at a rate of  $1.0 \text{ mg/kg min}^{-1}$  to determine its ability to restore normal sinus rhythm.

### Discussion

The replacement of the *tert*-butylaminoethanol side chain of a known  $\beta_2$ -sympathomimetic (1)<sup>1</sup> by the 3-*tert*butylamino-2-hydroxypropoxy moiety yielded **2a**, a potent new nonselective  $\beta$ -adrenergic blocking agent without  $\beta$ sympathomimetic and antiarrhythmic action. A similar modification of isoproterenol resulted in a sympathomimetic agent, 3, with activity reported to be similar to epinephrine.<sup>2</sup>

When the *tert*-butyl group of 2a was replaced by the 3,4-dimethoxyphenylethyl group, a  $\beta$ -adrenergic blocker, **2b** was obtained which was similar in potency to propranolol with only low myocardial depressant action. This analog, **2b**, possessed intrinsic  $\beta$ -sympathomimetic action at doses of 0.03 mg/kg or less. Analogs **2a** and **2b** were ineffective in reversing ouabain-induced cardiac arrhythmias. Preliminary studies indicated that **2b** exerted a threefold preference for blockade of myocardial  $\beta_1$ -receptors over  $\beta_2$ -receptors when the relative blockade of isoproterenol effects on heart rate, contractile force, and blood pressure were compared. Similar incorporation of the 3,4-dimethoxyphenylethyl group into the benzophenone (11)<sup>3</sup> and tetralone (12)<sup>4</sup> series of  $\beta$ -adrenergic blockers failed to yield analogs which were cardioselective or nondepressant.

In the present study, an apparent 3:1 selectivity ratio for 2b was observed. However, additional experiments are needed to quantitatively compare 2b with practolol which was reported to exert an eightfold cardioselective response in anesthetized dogs.<sup>5</sup> Unlike the present study, the practolol studies were designed to quantitatively differentiate between the  $\beta_1$  and  $\beta_2$  response (Table I).

#### **Experimental Section**

Melting points were taken in open capillary tubes on a Mel-Temp and are uncorrected. Each analytical sample was homogeneous by tlc and had ir, uv, and nmr spectra compatible with its structure. Combustion analysis for C, H, N, and Cl gave results within 0.4% of theory.

Methyl 3-Benzoyloxy-5-hydroxybenzoate (5). To a solution of 168 g (1.0 mol) of 4 in 2.0 l. of water was added 30 ml of 10% NaOH until pH 8 was reached. Benzoyl chloride (154 g, 1.1 mol) and 400 ml of 10% NaOH were added simultaneously to the warmed reaction mixture (40°) over a 30-min period. The reaction was stirred at  $30-35^{\circ}$  for 1 hr and extracted with CHCl<sub>3</sub> (2 × 750 ml). The combined CHCl<sub>3</sub> extracts were washed with water (1 × 350 ml) and dried over MgSO<sub>4</sub>. Evaporation of the CHCl<sub>3</sub> gave 252 g (92.8%) of the crude 5. Recrystallization of the material from benzene gave 159 g (58.5%), mp 110-112°, of crystalline 5 which was used without further purification.

Methyl 3-Benzoyloxy-5-benzyloxybenzoate (6). A mixture of 5 (418 g, 1.54 mol), benzyl bromide (387 g, 2.26 mol),  $K_2CO_3$  (310 g, 2.26 mol), and 4.1 l. of acetone was heated at reflux for 3 hr. The mixture was poured onto 3.3 l. of ice and extracted with CHCl<sub>3</sub> (2 × 2 l.). The CHCl<sub>3</sub> extracts were combined and washed with 10% NaOH (3.3 l.) and water (2 × 1.6 l.). The CHCl<sub>3</sub> phase was dried with MgSO<sub>4</sub> and evaporated to give an oily residue which was stirred with hexane (1.8 l.) at 10° for 1 hr. Crystalline material was collected by filtration and reslurried with hexane (1.3 l.) for 1 hr at 10°. The crystalline 6 was collected and dried to give 409 g (73.5%), mp 69-70°, used without further purification.

Methyl 3-Benzyloxy-5-hydroxybenzoate (7). A reaction mixture containing 409 g (1.13 mol) of 6, 102 g (0.55 mol) of p-toluenesulfonic acid, and 2.7 l. of MeOH was heated at reflux for 17 hr. The reaction mixture was evaporated to dryness; the crude residue obtained was dissolved in CHCl<sub>3</sub> (2.5 l.), washed with aqueous NaHCO<sub>3</sub> and water, and dried with MgSO<sub>4</sub> before the CHCl<sub>3</sub> phase was evaporated *in vacuo* to the crude product as an oil. Trituration of the residue with hexane yielded crystalline 7: yield 220 g (75.5%); mp 97-98°. Anal. (C<sub>15</sub>H<sub>14</sub>O<sub>4</sub>) C, H.

Methyl 3-Benzyloxy-5-(2,3-epoxypropoxy)benzoate (8). A methanolic solution (250 ml) containing 4.26 g (106 mmol) of NaOH, 250 ml of epichlorohydrin, and 25 g (96.8 mmol) of 7 was stirred at room temperature for 18 hr. The reaction mixture was evaporated to a residual oil which was dissolved in 500 ml of CHCl<sub>3</sub> and extracted with 10% NaOH ( $1 \times 100$  ml) and water ( $1 \times 100$  ml) before drying with anhydrous MgSO<sub>4</sub>. The CHCl<sub>3</sub> was evaporated and the crude expected product was obtained as a gum in 98% yield.

Methyl 3-Benzyloxy-5-[3-(tert-butylamino)-2-hydroxypropoxy]benzoate Hydrochloride (9a). A reaction mixture containing 29.9 g (94.8 mmol) of crude 8 and 250 ml of *tert*-butylamine dissolved in 250 ml of methanol was heated at reflux for 1 hr. After evaporation of the volatile components of the reaction mixture, the oily residue which remained was converted to a crystalline hydrochloride salt: yield 30.2 g (75.3%); mp 174-176°. Recrystallization of the product from toluene gave the analytical sample: mp 181-183°. Anal. (C<sub>22</sub>H<sub>29</sub>NO<sub>5</sub>·HCl) C, H, N, Cl.

3-Benzyloxy-5-[3-(tert-butylamino)-2-hydroxypropoxy]benzyl Alcohol (10a). To a suspension of 29.1 g (68.5 mmol) of 9a in 500 ml of THF cooled at 0° was added 5.20 g (137 mmol) of LiAlH<sub>4</sub>. The resultant mixture was refluxed 18 hr. After the excess LiAlH<sub>4</sub> and complex had been destroyed by the addition of water, the reaction mixture was diluted with 500 ml of CHCl<sub>3</sub> and the precipitate was removed by filtration. The organic filtrate was washed with water (1 × 500 ml), dried with MgSO<sub>4</sub>, and evaporated to give the crude solid 10a: yield 20.7 g (84.0%); mp 99-105°. The analytical sample was obtained from cyclohexane: mp 105-107°. Anal. (C<sub>21</sub>H<sub>29</sub>NO<sub>4</sub>) C, H, N.

3-[3-(tert-Butylamino)-2-hydroxypropoxy]-5-hydroxybenzyl Alcohol Fumarate (2a). An ethanol solution (250 ml) containing 19.7 g (54.7 mmol) of 10a was hydrogenated over 8 g of 10% Pd/C catalyst until hydrogen uptake had ceased. The catalyst was removed by filtration through a Celite pad and the filtrate obtained was evaporated to a gummy residue. A crystalline fumerate salt was obtained in analytical purity from MeOH-Et<sub>2</sub>O: mp 254-255° dec. Anal. (C<sub>14</sub>H<sub>23</sub>NO<sub>4</sub>·0.5C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) C, H, N.

Methyl 3-Benzyloxy-5-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]benzoate (9b). A reaction mixture containing 10.0 g (31.9 mmol) of 8, 25 g (138 mmol) of 3,4-dimethoxyphenylethylamine, and 100 ml of methanol was heated at reflux for 1 hr. Evaporation of the reaction mixture gave a residual oil which was dissolved in CHCl<sub>3</sub> (500 ml), extracted with 1 N HCl ( $2 \times 250$ ml) and 1 N NaOH (500 ml), and dried with anhydrous MgSO<sub>4</sub>. Evaporation of the CHCl<sub>3</sub> gave a residual solid which upon trituration with a Et<sub>2</sub>O-hexane mixture gave 14.6 g (92.4%) of crystalline product: mp 75-85°. The analytical material was obtained by recrystallization from toluene: mp 94-95°. Anal. (C<sub>28</sub>H<sub>33</sub>NO<sub>7</sub>) C, H, N.

3-[3-(3,4-Dimethoxyphenylethylamino)-2-hydroxypropoxy]-5-hydroxybenzyl Alcohol Fumarate (2b). To a suspension of 3.11 g (82.0 mmol) of LiAlH<sub>4</sub> in 250 ml of dry THF was added a THF solution (250 ml) containing 20.3 g (41.0 mmol) of methyl 3-benzyloxy-5-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]benzoate. The resulting reaction mixture was refluxed for 3 hr before the excess LiAlH<sub>4</sub> and complex were destroyed by the careful addition of water. The white precipitate which formed was removed by filtration and the filtrate obtained was evaporated *in* vacuo and gave a quantitative yield of the crude 10b as a strawcolored oil.

An ethanol solution (150 ml) containing 19.6 g (41.2 mmol) of 10b was hydrogenated over 5.0 g of 10% Pd/C catalyst until hydrogen uptake had ceased. The catalyst was removed by filtration and the filtrate was evaporated to give an oily residue as product.

A crystalline fumarate salt was obtained from 1-PrOH: yield 14.1 g; mp 183-186° dec. The analytical sample was obtained by one recrystallization from MeOH-Et<sub>2</sub>O: mp 189-191° dec. Anal.  $(C_{20}H_{27}NO_6 \cdot 0.5C_4H_4O_4)$  C, H, N.

2-[3-(3,4-Dimethoxyphenylethylamino)-2-hydroxypropoxy]benzophenone Hydrogen Oxalate (11). A methanolic solution (100 ml) containing 10.0 g (39.3 mmol) of 2-(2,3-epoxypropoxy)benzophenone<sup>3</sup> and 22.6 g (125 mmol) of 3,4-dimethoxyphenylethylamine was heated at reflux for 2 hr. The reaction mixture was evaporated to remove the volatile components and the residue obtained was dissolved in CHCl<sub>3</sub> (500 ml). The CHCl<sub>3</sub> solution was washed with 3 N HCl (3 × 500 ml), 1 N NaOH (1 × 500 ml), and H<sub>2</sub>O (1 × 500 ml) before being dried with MgSO<sub>4</sub> and evaporated to give 15.8 g (92.2%) of the expected product as an oil. The product was purified as an oxalate salt by recrystallization from 2-PrOH: yield 12.4 g (61.1%); mp 129-130°. Anal. (C<sub>26</sub>H<sub>29</sub>NO<sub>5</sub>·C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.

5-[3-(3,4-Dimethoxyphenylethylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone Hydrogen Oxalate (12). A reaction mixture containing 13.4 g (61.6 mmol) of 3,4-dihydro-5-(2,3-epoxypropoxy)-1(2H)-naphthalenone,<sup>4</sup> 100 ml of MeOH, and 53.7 g (295 mmol) of 3,4-dimethoxyphenylethylamine was heated at reflux for 1 hr. The mixture was evaporated to an oily residue which was dissolved in CHCl<sub>3</sub> (500 ml) and washed with 3 N HCl (3 × 500 ml), 20% NaOH (1 × 100 ml), and H<sub>2</sub>O (1 × 500 ml). The CHCl<sub>3</sub> solution was dried (MgSO<sub>4</sub>) and evaporated in vacuo to give the expected product as a crude oil: yield 13.5 g (54.9%). The product was purified as an oxalate salt by recrystallization from 2-PrOH: mp 152-154°. Anal. (C<sub>23</sub>H<sub>29</sub>NO<sub>5</sub>·C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>) C, H, N.

Acknowledgments. The authors are indebted to the Chemical Development Department under the supervision of Dr. A. W. Ruddy and the Analytical and Physical Chemistry Department under the supervision of Mr. A. D. Lewis. In particular we wish to thank Mr. R. Novack and Mr. F. H. McMillan for large-scale preparation of intermediates and Mrs. U. Zeek for microanalyses. We also thank Mr. J. Barker and Ms. D. Dugan for their technical assistance in the pharmacologic studies.

#### References

- C. F. Schwender, B. R. Sunday, J. Shavel, Jr., and R. E. Giles, J. Med. Chem., 17, 1112 (1974).
- (2) V. Smejkal, V. Trcka, M. Vanecek, J. Weichet, and L. Blaha, *Therapie*, 22, 1343 (1967).
- (3) C. F. Schwender, R. E. Pike, B. R. Sunday, and J. Shavel, Jr., J. Med. Chem., 16, 585 (1973).
- (4) C. F. Schwender, S. Farber, C. Blaum, and J. Shavel, Jr., J. Med. Chem., 13, 684 (1970).
- (5) B. Basil, R. Jordan, A. H. Loveless, and D. R. Maxwell, Brit. J. Pharmacol., 48, 198 (1973).

## Hashish.<sup>1</sup> Importance of the Phenolic Hydroxyl Group in Tetrahydrocannabinols

D. B. Uliss, H. C. Dalzell, G. R. Handrick, J. F. Howes, and R. K. Razdan\*

Sheehan Institute and Sharps Associates (SISA), Cambridge, Massachusetts 02138. Received August 5, 1974

Optically active  $\Delta^{9}$ - and  $\Delta^{8}$ -tetrahydrocannabinols (THC's), cannabidiol and racemic  $\Delta^{9}$ -cis-THC, and their corresponding analogs ( $\mathbf{lb} \rightarrow \mathbf{4b}$ ) in which the positions of the phenolic hydroxyl group and the *n*-C<sub>5</sub> side chain have been interchanged are compared in selected pharmacological tests in mice. The results indicate that the phenolic hydroxyl group in the 1 position in THC's is very important for eliciting activity and that cannabidiol and  $\Delta^{9}$ -cis-THC possess weak CNS depressant properties.

To date over 30 cannabinoids have been isolated from the plant *Cannabis sativa* and it is generally accepted that the principal compounds of pharmacological interest are  $\Delta^{9}$ - and  $\Delta^{8}$ -6a,10a-*trans*-tetrahydrocannabinols (THC's). In laboratory animals  $\Delta^{9}$ - and  $\Delta^{8}$ -THC's cause CNS depression and ataxia. The characteristic effect of THC's, which distinguishes them from all other psychoactive drugs, is a postural arrest phenomenon with relaxed staring associated with hyperexcitability to external stimuli ("popcorn effect").<sup>2</sup> On the basis of behavioral tests in monkeys, Edery, et al.,<sup>3</sup> have reported some structureactivity relationships (SAR) in the THC series. However, little is known about the importance of the phenolic hydroxyl group in naturally occurring THC's. In monkeys, the acetates of  $\Delta^{9}$ - and  $\Delta^{8}$ -THC's have  $\frac{1}{10}$  to  $\frac{1}{2}$  the activity of the parent compounds and the methyl ethers are essentially inactive.<sup>3</sup> We have found that the aminoalkyl esters of  $\Delta^{9}$ -THC are nearly equiactive with the parent